Trinity Capital Bolsters Candel Therapeutics with $130M for Cancer Therapies

Trinity Capital Inc. has announced a significant $130 million growth capital investment in Candel Therapeutics, a pioneering company dedicated to developing viral immunotherapies for cancer. This strategic funding aims to enhance Candel’s capabilities in crafting innovative treatments that could transform the landscape of cancer care. With Trinity’s financial backing, Candel is well-positioned to accelerate research and development efforts, potentially revolutionizing how cancer is treated. 

Candel Therapeutics is at the forefront of biotechnological advancements, focusing on harnessing the power of viral immunotherapies to combat various forms of cancer. This innovative approach involves using engineered viruses to target and destroy cancer cells, a method that holds promise for more effective and less invasive cancer treatments. By securing substantial support from Trinity Capital, Candel can expedite its development processes and bring these groundbreaking therapies closer to reality. The investment not only represents financial backing but also underscores the growing confidence in viral immunotherapy as a viable cancer treatment option. Trinity Capital, known for strategically funding high-potential companies, sees this partnership as an opportunity to make significant strides in cancer therapy.